This comprehensive blend has been researched to prove to target four distinct phases of tissue regeneration simultaneously in laboratory models: regulation of inflammation (KPV), promotion of angiogenesis (BPC-157), facilitation of cell migration (TB-500), and enhancement of collagen deposition (GHK-Cu)
It is FDA-approved for type 2 diabetes (FDA-approved 2022)
Cells were treated with indicated concentrations (0, 0.001, 0.005, 0.02, 0.1 mmol/L) of buthionine sulfoximine for 24 hours and then treated with hydrogen peroxide (0, 10, 20 mol/L) for 5 hours
Although not FDA-approved, compounded versions are often prescribed under the same guidelines as Wegovy
mTOR-dependent phosphorylation controls TFEB nuclear export
Always consult with a healthcare professional before starting any supplementation to ensure safety and efficacy